Altoida

Enabling Early Detection for a Healthier Brain

Revolutionizing neurology diagnostics with our digital NeuroMarker Platform designed to rapidly detect early cognitive decline and empower healthcare providers to intervene sooner—when treatment is most effective.
Learn more about our platform

Current Diagnostics Miss Early Detection

Leading to Long Wait Times for Treatment Decisions

2,000

People per day progress to more advanced stages of Alzheimer’s disease.

20

U.S. states are “dementia neurology deserts” as shrinking provider networks and rising demand have created a critical neurologist shortage, labeled a “grave threat” by the American Academy of Neurology.

70+

Months a patient will wait from cognitive complaint to a treatment decision with current standard care by 2033. The current wait is 12 months.
Early detection of mild cognitive impairment (MCI) and Alzheimer’s is often delayed due to limited access to specialized diagnostics, leaving some patients waiting years for a diagnosis. Current standard of care, paper-based cognitive assessments can be subjective, misdiagnose up to 30% of cases and fail to capture subtle cognitive and functional changes, further delaying treatment decisions and hindering early intervention.  These challenges lead to significant delays in care, increasing the burden on patients, caregivers, and already overextended healthcare providers.

Advancing Early Detection for

Faster, More Effective Intervention

The aim of Altoida’s groundbreaking NeuroMarker Platform is to empower clinicians with real-time insights during a single office visit. Using machine learning and augmented reality to simulate instrumental activities of daily living (iADL), it is designed to detect the earliest signs of cognitive impairment. Developed for faster diagnosis, this platform is intended to help healthcare providers intervene sooner, giving millions of patients a better chance at receiving timely, effective treatment.

Discover our Platform

Pioneering

Early Detection in Cognitive Health

Our NeuroMarker Platform is built on two decades of rigorous, peer-reviewed clinical research and scientific validation. Through numerous clinical studies, it has been proven to be highly effective in identifying MCI and early signs of Alzheimer’s disease, our proprietary technology also has potential applications for other related dementias. Founded on robust clinical insights and continuous evidence generation, our mission is to empower healthcare providers with the tools they need to make earlier, more informed decisions in patient care.

Read our Latest Breakthroughs

Proven: Early & Accurate Detection of Prodromal Alzheimer's Disease

The Altoida NeuroMarker Platform can effectively identify preclinical and prodromal Alzheimer's disease quicker than traditional neuropsychological tests without any learning effects.
Read the RADAR-AD Study

The Vital Role of Diagnostics in

Advancing Alzheimer's Research

Explore recent studies that highlight how innovative diagnostics are driving breakthroughs in Alzheimer's diagnosis and treatment.

Approximately 10-15% of Parkinson’s cases are believed to be attributed to genetic causes.
10.25.22

Patients Ask: Is Parkinson's Disease Hereditary?

While Parkinson’s disease can be hereditary, it’s very rare. Approximately 10 to 15% of Parkinson’s cases are believed to be due to genetic causes.
Hypothyroidism, or underactive thyroid, in older adults has been linked to elevated dementia risk.
10.20.22

Is There a Connection Between Your Thyroid and Dementia Risk?

Emerging research suggests a link between your thyroid and dementia risk. Adults 65+ with a history of hypothyroidism had an 81% increased risk of dementia.
While previous research has linked gum disease to cardiovascular disease, it has recently been linked to Alzheimer’s disease.
10.18.22

Gum Disease and Alzheimer's: Understanding the Research

The connection between gum disease and Alzheimer’s suggests that gum disease may accelerate Alzheimer’s disease progression and cognitive decline.
A Parkinson’s patient in the middle to late stages of Parkinson’s disease talking with a caregiver while using a walker.
10.13.22

Patients Ask: What Are the Stages of Parkinson's Disease?

The stages of Parkinson’s disease according to the updated Hoehn and Yahr staging scale are 0, 1,1.5, 2, 2.5, 3, 4, and 5, based on clinical disability.
Vitamin D, while known for its role in skeletal health, has been linked to brain health
10.11.22

Understanding Vitamin D Deficiency Effects on the Brain

Emerging research suggests vitamin D deficiency may affect brain health. Vitamin D deficiency has been linked to dementia as well as depression.
A Parkinson’s patient in the middle to late stages of Parkinson’s disease talking with a caregiver while using a walker.
10.06.22

Advanced Stages of Alzheimer's: Understanding the Stages

The advanced stages of Alzheimer’s disease (stages 4 and 5) are moderate dementia due to Alzheimer’s disease and severe dementia due to Alzheimer’s.
1 … 4 5 6 7 8 … 26
More Resources

News

Shaping the Future of Cognitive Health

The latest coverage on our work. Explore how Altoida’s technology is shaping the future of early detection and transforming patient care.
1 … 4 5 6 7 8 … 31
View all News

Get in Touch with Us

Whether you have questions about our platform or want to explore partnership opportunities, we’re here to help. Our team is ready to provide you with the answers and support you need.